arrow
A

Arun J. Sanyal

virginia commonwealth university
H指数:166
被引数:15.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Short-Term Risk Stratification in Alcohol-Associated Hepatitis: Small HDL Particles and Inflammation Vulnerability Index Values Improve Model for End-Stage Liver Disease

酒精性肝炎的短期风险分层:小HDL颗粒和炎症易损性指数值改善了终末期肝病模型

2026-09-220
OAAI
Author Correction: Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial

作者更正:索沃杜肽在肥胖和代谢功能障碍相关脂肪性肝病成人患者中的应用:SYNCHRONIZE-MASLD,一项随机、双盲、安慰剂对照的3期临床试验

2026-08-250
OAAI
Meta‐Analysis: Enhanced Liver Fibrosis ( ELF ) Test for Identifying Significant Fibrosis, Advanced Fibrosis, and Cirrhosis in Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease

荟萃分析:增强型肝纤维化(ELF)检测用于识别代谢功能障碍相关脂肪性肝病患者的显著纤维化、进展期纤维化和肝硬化

2026-08-240
OAAI
Validation of AGILE 3+ and AGILE 4 Scores for Assessing Advanced Fibrosis and Cirrhosis in Indian Patients With Nonalcoholic Fatty Liver Disease: An Indian Consortium on Non-alcoholic Fatty Liver Disease Study

AGILE 3+和AGILE 4评分在评估印度非酒精性脂肪肝病患者中晚期肝纤维化和肝硬化的有效性验证:印度非酒精性脂肪肝病研究联盟研究

2026-08-010
PRE
The global cardiovascular-kidney-liver-metabolic burden from 1990 to 2023

1990年至2023年全球心血管-肾脏-肝脏-代谢负担

2026-08-010
OAAI
AI digital pathology as a key tool providing in-depth understanding of the progression and regression of MASH and fibrosis in male mouse models

AI数字病理学作为关键工具,为深入了解雄性小鼠模型中MASH和纤维化的进展与消退提供支持

2026-07-220
OA
The metabolic vulnerability index predicts outcomes in patients with metabolic dysfunction associated steatotic liver disease

代谢脆弱性指数预测代谢功能障碍相关脂肪性肝病患者的预后

2026-06-230
OAAI
Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial

肥胖和代谢功能障碍相关的脂肪变性肝病成人的Survodutide: synchrone-masld,一项随机,双盲,安慰剂对照的3期试验

2026-06-070
OAAI
Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial

Semaglutide对高危肝纤维化患者的肝纤维化和心脏结局的影响: 一项选择性随机试验的预设分析

2026-04-020
OAAI
Histological severity and hepatic outcomes in patients with metabolic dysfunction-associated steatotic liver disease and discrepant FIB-4 and liver stiffness measurement

代谢功能障碍相关脂肪性肝病且FIB-4与肝硬度测量结果不一致患者的组织学严重程度和肝脏结局

2026-01-011
PRE